Jump to main content
Jump to site search

Issue 12, 2015
Previous Article Next Article

Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders

Author affiliations

Abstract

Neurodegenerative disease appears as a result of genomic lesions which lead to alterations at multiple levels like genomic product and biological pathways. It involves destruction of existing neuroprotective mechanisms inside body which initiates the cellular changes involved in processing of these insidious disorders. Phosphodiesterases that are crucial for degradation of cAMP and cGMP have been puissant in memory retrieval. Overwhelming therapeutic credential of PDE5 inhibitors have triggered interests in PDE inhibitors. Almost every PDE member has marked its presence in the CNS devising them as enticing sources of novel protein targets for curing ND. This review describes a selection of recent findings and advancements with regards to PDE genes that are crucial for exploring pharmacological routes to ND.

Graphical abstract: Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders

Back to tab navigation

Publication details

The article was received on 18 Sep 2015, accepted on 05 Nov 2015 and first published on 12 Nov 2015


Article type: Review Article
DOI: 10.1039/C5MD00419E
Med. Chem. Commun., 2015,6, 2063-2080

  •   Request permissions

    Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders

    T. Umar and N. Hoda, Med. Chem. Commun., 2015, 6, 2063
    DOI: 10.1039/C5MD00419E

Search articles by author

Spotlight

Advertisements